Details

Autor(en) / Beteiligte

• Blanco-Palmero, V. A.
• Azcárate-Díaz, F. J.
• Ruiz-Ortiz, M.
• Laespada-García, M. I.
• Rábano-Suárez, P.
• Méndez-Guerrero, A.
• Aramendi-Ramos, M.
• Eguiburu, J. L.
• Pérez-Rivilla, A.
• Marchán-López, A.
• Rubio-Fernández, M.
• Carro, E.
• González de la Aleja, J.

Titel

Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms

Ist Teil von

• Journal of neurology, 2021-09, Vol.268 (9), p.3116-3124

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• SARS-CoV-2 infection can associate diverse neurological manifestations. Several studies have provided proof to support the theory of neurotropic involvement of SARS-CoV-2. Alpha-synuclein has been described as a native antiviral factor within neurons, and upregulation of this protein can be seen in animals that suffered other neuroinvasive infections. To assess if increased expression of this protein takes place in COVID-19 patients with neurological symptoms, we analyzed serum total alpha-synuclein levels in three groups: seven COVID-19 patients with myoclonus, Parkinsonism and/or encephalopathy; thirteen age- and sex-matched COVID-19 patients without neurological involvement and eight age- and sex-matched healthy controls. We did not find differences among them. In a subset of four patients, the change in serum alpha-synuclein before and after the onset of neurological symptoms was not significant either. Cerebrospinal fluid alpha-synuclein levels were also similar between neurological COVID-19 and healthy controls. Overall, these results cannot support the hypothesis of alpha-synuclein upregulation in humans with neurological symptoms in COVID-19. Further research taking into account a larger group of COVID-19 patients including the whole spectrum of neurological manifestations and disease severity is needed.